Zai Lab (ZLAB) said Tuesday that its Tumor Treating Fields therapy for patients with pancreatic cancer received an Innovative Medical Device Designation from China's National Medical Products Administration.
The company said that the designation was awarded based on "positive" results from its phase 3 PANOVA-3 trial, which had tested the use of the therapy simultaneously with gemcitabine and nab-paclitaxel as a first-line treatment for unresectable, locally advanced pancreatic adenocarcinoma compared to gemcitabine and nab-paclitaxel alone.
Zai Lab said the designation enables the company to make use of an expedited approval procedure. The company said it is on track for a regulatory submission in China in H2 2025.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。